Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 7.53 USD 1.07% Market Closed
Market Cap: 969m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+48%
Revenue
Forecast
+12%
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

NEO Price Targets Summary
Neogenomics Inc

Wall Street analysts forecast NEO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NEO is 11.17 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.

NEO Lowest Forecast
Wall Street Target
8.08 USD
7% Upside
NEO Average Forecast
Wall Street Target
11.17 USD
48% Upside
NEO Highest Forecast
Wall Street Target
15.75 USD
109% Upside
Lowest
Price Target
8.08 USD
7% Upside
Average
Price Target
11.17 USD
48% Upside
Highest
Price Target
15.75 USD
109% Upside
Neogenomics Inc Competitors:
Price Targets
F
FLB
Fluidigm Corp
102% Upside
DHR
Danaher Corp
24% Upside
1SXP
SCHOTT Pharma AG & Co KgaA
19% Upside
SHC
Sotera Health Co
30% Upside
F
FLB
Fluidigm Corp
102% Upside
DHR
Danaher Corp
24% Upside
1SXP
SCHOTT Pharma AG & Co KgaA
19% Upside
SHC
Sotera Health Co
30% Upside
ABSI
Absci Corp
229% Upside
MEDP
Medpace Holdings Inc
4% Downside
688222
HitGen Inc
1% Upside
RGEN
Repligen Corp
44% Upside

Revenue
Forecast

Revenue Estimate
Neogenomics Inc

For the last 8 years the compound annual growth rate for Neogenomics Inc's revenue is 14%. The projected CAGR for the next 3 years is 12%.

14%
Past Growth
12%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Neogenomics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Neogenomics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-64%
Average Miss
What are analyst estimates?

See Also

Summary
NEO intrinsic value, competitors valuation, and company profile.
DCF Valuation
NEO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NEO stock valuation using valuation multiples.
Wall Street Estimates
NEO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NEO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NEO's stock price target?
Price Target
11.17 USD

According to Wall Street analysts, the average 1-year price target for NEO is 11.17 USD with a low forecast of 8.08 USD and a high forecast of 15.75 USD.

What is Neogenomics Inc's Revenue forecast?
Projected CAGR
12%

For the last 8 years the compound annual growth rate for Neogenomics Inc's revenue is 14%. The projected CAGR for the next 3 years is 12%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 266,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.